Patents Assigned to Asahi Kasei Pharma Corporation
  • Publication number: 20200347046
    Abstract: A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.
    Type: Application
    Filed: December 25, 2018
    Publication date: November 5, 2020
    Applicant: Asahi Kasei Pharma Corporation
    Inventors: Daisuke SHIKANAI, Noriko ISHIGURO, Osamu OMORI
  • Publication number: 20200289621
    Abstract: According to the present invention, a liquid pharmaceutical preparation containing teriparatide or a salt thereof having excellent physical properties, the liquid pharmaceutical preparation containing teriparatide or a salt thereof, and at least one or more members of inorganic salts and/or organic salts is provided.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 17, 2020
    Applicant: ASAHI KASEI PHARMA CORPORATION
    Inventors: Kohei MIYABE, Takahiro YAMAGUCHI, Yasuhiro MATSUNAWA, Narumi WATANABE
  • Publication number: 20200289622
    Abstract: A liquid pharmaceutical preparation for subcutaneous administration in human containing 28.2 ?g of teriparatide or a salt thereof (Component 1) in a unit dose in terms of teriparatide, wherein the Component 1 concentration is from 80 to 240 ?g/mL. This liquid pharmaceutical preparation is excellent in the viewpoint of pharmacokinetics.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 17, 2020
    Applicant: ASAHI KASEI PHARMA CORPORATION
    Inventors: Kohei MIYABE, Atsushi OSE, Yuki SATO, Toshiyuki KODAMA, Yasuhiro MATSUNAWA, Hikaru YAMAMOTO
  • Patent number: 10709767
    Abstract: A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 14, 2020
    Assignees: KINKI UNIVERSITY, ASAHI KASEI PHARMA CORPORATION
    Inventors: Atsufumi Kawabata, Hideaki Suzuki
  • Patent number: 10683335
    Abstract: Provided herein are freeze-dried preparations comprising a high-purity parathyroid hormone (PTH) peptide and one or more PTH analogs, and methods for the production thereof. Also provided is a test method for detecting PTH analogs to confirm the purity of a freeze-dried preparation containing PTH peptide, and the like.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: June 16, 2020
    Assignee: ASAHI KASEI PHARMA CORPORATION
    Inventors: Fumihide Nishio, Takuji Maejima, Yoshiro Mitome
  • Publication number: 20200101139
    Abstract: An object of the present invention is to provide an effective and safe medicament having effects for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by administration of an anti-malignant tumor agent, oxaliplatin, in a human cancer patient receiving an anti-malignant tumor treatment with oxaliplatin. There is provided a medicament for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by oxaliplatin in an anti-malignant tumor treatment consisting of repetition of a single cycle comprising intravenous administration of oxaliplatin to a human cancer patient and following drug withdrawal, which contains thrombomodulin for intravenously administering 0.06 mg/kg of thrombomodulin once per said single cycle of the treatment on the first day of each said cycle as an active ingredient.
    Type: Application
    Filed: October 18, 2019
    Publication date: April 2, 2020
    Applicant: Asahi Kasei Pharma Corporation
    Inventors: Takumi SAKAI, Genichi KUSAKAWA, Yugo UCHIDA
  • Patent number: 10588945
    Abstract: [Problem] To provide an agent for preventing the onset of idiopathic osteonecrosis of the femoral head and/or suppressing the progress of the same. [Solution] An agent for preventing the onset of idiopathic osteonecrosis of the femoral head and/or suppressing the progress of the same comprising parathyroid hormone or a derivative thereof as an active ingredient, characterized by being administered intermittently.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: March 17, 2020
    Assignees: ASAHI KASEI PHARMA CORPORATION, NATIONAL UNIVERSITY CORPORATION ASAHIKAWA MEDICAL UNIVERSITY
    Inventors: Hiromasa Tanino, Hiroshi Ito
  • Publication number: 20200002744
    Abstract: An object of the present invention is to provide a highly versatile, simple and safe method for measuring Lp-PLA2 activity. Another object of the present invention is to provide an accurate and highly sensitive method for measuring Lp-PLA2 activity. Provided is a method for measuring lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in a sample containing Lp-PLA2, the method comprising the following steps (A) to (C): (A) converting PAFs into lyso-PAFs by reacting the PAFs with the Lp-PLA2 in the sample; (B) hydrolyzing the lyso-PAFs produced in the step (A) with an enzyme (lyso-PAF-PLD) to obtain hydrolysate; and (C) measuring Lp-PLA2 activity in the sample by utilizing a quantitative change attributable to the hydrolysate obtained in step (B) as an indicator.
    Type: Application
    Filed: June 15, 2017
    Publication date: January 2, 2020
    Applicant: ASAHI KASEI PHARMA CORPORATION
    Inventors: Shinichi SAKASEGAWA, Saki YAMAURA, Daisuke SUGIMORI
  • Patent number: 10472665
    Abstract: The present invention provides a measuring method for at least one of a kinase forward reaction substrate, a phosphorylated product thereof, and a precursor thereof, and includes a step of conducting an enzymatic cycling reaction by bringing at least a kinase, a first nucleotide coenzyme of the kinase, and a second nucleotide coenzyme having a different nucleoside moiety from the first nucleotide coenzyme into contact with a sample; a step of detecting a signal corresponding to a change of at least one of the first nucleotide coenzyme and a conversion product thereof, and the second nucleotide coenzyme and a conversion product thereof; and (3) a step of calculating, on the basis of the detected change of the signal, an amount of the kinase forward reaction substrate and/or the phosphorylated product thereof contained in the sample.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: November 12, 2019
    Assignee: ASAHI KASEI PHARMA CORPORATION
    Inventors: Shigeru Ueda, Shinichi Sakasegawa
  • Publication number: 20190170762
    Abstract: An object of the present invention is to provide a method of measuring a glycated-albumin (GA) value traceable to a certified GA value conveniently at a low cost in a short period of time. A method of measuring a GA value traceable to the certified GA value includes the following steps: A1) determining Regression equation III by steps including the following b), c), and e0) to h); b) determining a GA concentration [L] (A) of two or more GA certified reference materials having respectively different certified GA values; c) measuring a GA-derived absorbance (D) of the two or more GA certified reference materials; e0) creating Linear equation II0 having an intercept of zero; f) determining two or more GA concentrations[P] (E) proportionate to the GA-derived absorbance (D) according to Equation II0; g) determining two or more GA values (F); and h) creating Regression equation III.
    Type: Application
    Filed: July 19, 2017
    Publication date: June 6, 2019
    Applicant: ASAHI KASEI PHARMA CORPORATION
    Inventor: Ryosuke KOGUMA
  • Publication number: 20180185454
    Abstract: [Problem] To provide an agent for preventing the onset of idiopathic osteonecrosis of the femoral head and/or suppressing the progress of the same. [Solution] An agent for preventing the onset of idiopathic osteonecrosis of the femoral head and/or suppressing the progress of the same comprising parathyroid hormone or a derivative thereof as an active ingredient, characterized by being administered intermittently.
    Type: Application
    Filed: July 4, 2016
    Publication date: July 5, 2018
    Applicants: ASAHI KASEI PHARMA CORPORATION, NATIONAL UNIVERSITY CORPORATION ASAHIKAWA MEDICAL UNIVERSITY
    Inventors: Hiromasa TANINO, Hiroshi ITO
  • Patent number: 10011643
    Abstract: [Problem] Provided is a freeze-dried preparation containing high-purity PTH peptide and a method for the production thereof. Also provided is a test method for PTH analogs to confirm the purity of a freeze-dried preparation containing PTH peptide, and the like. [Solution] In the present invention, the presence of PTH analogs produced during the manufacturing process of a freeze-dried preparation containing PTH peptide was confirmed. The production of these PTH analogs was also discovered to be markedly prevented or reduced by controlling exposure of the solution containing PTH peptide and the like to air environments within a pharmaceutical production facility.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: July 3, 2018
    Assignee: ASAHI KASEI PHARMA CORPORATION
    Inventors: Fumihide Nishio, Takuji Maejima, Yoshiro Mitome
  • Patent number: 10000791
    Abstract: A measurement method for human pancreatic lipase activity in a sample, includes bringing a bile acid that makes a pH for giving a maximum value of human pancreatic lipase activity to be lower than 7.7, a diglyceride and a colipase into contact with the sample at pH 7.4 or lower; and detecting a signal amount varying in accordance with the human pancreatic lipase activity in the sample, and the bile acid is a bile acid containing: one of or two or more of a-type bile acids selected from the group consisting of GDCA, GCDCA, TDCA, TCDCA and salts thereof; and/or a combination of one of or two or more of b-1-type bile acids selected from the group consisting of GCA, GUDCA, TCA, TUDCA and salts thereof, and one of or two or more of b-2-type bile acids selected from the group consisting of DCA, CDCA and salts thereof.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: June 19, 2018
    Assignee: ASAHI KASEI PHARMA CORPORATION
    Inventors: Shigeru Ueda, Shinichi Sakasegawa
  • Publication number: 20170306389
    Abstract: The present invention provides a measuring method for at least one of a kinase forward reaction substrate, a phosphorylated product thereof, and a precursor thereof, and includes a step of conducting an enzymatic cycling reaction by bringing at least a kinase, a first nucleotide coenzyme of the kinase, and a second nucleotide coenzyme having a different nucleoside moiety from the first nucleotide coenzyme into contact with a sample; a step of detecting a signal corresponding to a change of at least one of the first nucleotide coenzyme and a conversion product thereof, and the second nucleotide coenzyme and a conversion product thereof; and (3) a step of calculating, on the basis of the detected change of the signal, an amount of the kinase forward reaction substrate and/or the phosphorylated product thereof contained in the sample.
    Type: Application
    Filed: September 18, 2015
    Publication date: October 26, 2017
    Applicant: ASAHI KASEI PHARMA CORPORATION
    Inventors: Shigeru UEDA, Shinichi SAKASEGAWA
  • Patent number: 9790492
    Abstract: [Problem] To provide the following: an agent for treating cancer, particularly an agent for inhibiting cancer cell proliferation or an agent for inhibiting or preventing cancer metastasis; drug that uses the agent; a method for assessing the effect of cancer treatment; a method for estimating the prognosis of cancer treatment; a method for screening for a substance having a cancer proliferation-inhibiting effect; and a method for screening a substance having a cancer metastasis-impeding effect. [Solution] Provided is a drug containing a nucleic acid formed from a nucleotide sequence having sequence identity of 70% or greater with at least sequence No. 1 or No. 2, wherein the nucleic acid shows protein expression-inhibiting activity.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: October 17, 2017
    Assignees: NATIONAL CANCER CENTER, ASAHI KASEI PHARMA CORPORATION
    Inventors: Takahiro Ochiya, Fumitaka Takeshita
  • Patent number: 9592275
    Abstract: A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: March 14, 2017
    Assignee: ASAHI KASEI PHARMA CORPORATION
    Inventors: Kazuhisa Tsuruta, Yoshikazu Aoki, Yutaka Osawa, Inder Kaul
  • Publication number: 20170037443
    Abstract: The present invention provides a method for measuring the concentration of an analyte in a test solution wherein the analyte is mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A, comprising the following steps (p) and (q): (p) a step of allowing an enzyme that catalyzes a reaction represented by Reaction Formula 1 and an enzyme that catalyzes a reaction represented by Reaction Formula 2 to act on a test solution containing mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A in the presence of a hydrogen acceptor X, a hydrogen donor Y, and coenzyme A; and (q) a step of measuring an amount of: a reduced hydrogen acceptor X that is produced; or an oxidized hydrogen donor Y that is produced; or a hydrogen acceptor X that is decreased; or a hydrogen donor Y that is decreased, wherein the hydrogen donor Y and the reduced hydrogen acceptor X are not the same.
    Type: Application
    Filed: August 11, 2016
    Publication date: February 9, 2017
    Applicant: ASAHI KASEI PHARMA CORPORATION
    Inventor: Takeshi MATSUOKA
  • Patent number: 9555080
    Abstract: A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: January 31, 2017
    Assignee: Asahi Kasei Pharma Corporation
    Inventors: Kazuhisa Tsuruta, Yoshikazu Aoki, Yutaka Osawa, Inder Kaul
  • Publication number: 20160331813
    Abstract: A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.
    Type: Application
    Filed: August 2, 2016
    Publication date: November 17, 2016
    Applicant: ASAHI KASEI PHARMA CORPORATION
    Inventors: Kazuhisa TSURUTA, Yoshikazu AOKI, Yutaka OSAWA, Inder KAUL
  • Patent number: 9458491
    Abstract: The present invention provides a method for measuring the concentration of an analyte in a test solution wherein the analyte is mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A, comprising the following steps (p) and (q): (p) a step of allowing an enzyme that catalyzes a reaction represented by Reaction Formula 1 and an enzyme that catalyzes a reaction represented by Reaction Formula 2 to act on a test solution containing mevalonic acid and/or 3 -hydroxymethylglutaryl coenzyme A in the presence of a hydrogen acceptor X, a hydrogen donor Y, and coenzyme A; and (q) a step of measuring an amount of: a reduced hydrogen acceptor X that is produced; or an oxidized hydrogen donor Y that is produced; or a hydrogen acceptor X that is decreased; or a hydrogen donor Y that is decreased, wherein the hydrogen donor Y and the reduced hydrogen acceptor X are not the same.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: October 4, 2016
    Assignee: ASAHI KASEI PHARMA CORPORATION
    Inventor: Takeshi Matsuoka